2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
The O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham is Alabama’s only cancer center designated by the National Cancer Institute and is a national leader in driving cancer research, advancing new cancer treatments, engaging communities in cancer prevention and early detection initiatives, and training the next generation of cancer physicians and scientists. Since it was established in 1971, the Cancer Center has been continuously funded for 48 years and has become a world-renowned institution for cancer research, cancer care and the delivery of that care to all people.
March 22, 2023
Video
A review of systemic treatment options used in polycythemia vera and the roles these play in the current treatment landscape.
March 22, 2023
Video
A brief overview of myeloproliferative neoplasms and the associated signs and symptoms commonly presenting in patients.
March 20, 2023
Article
Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.
December 06, 2022
Video
Rodney Rocconi, MD, discusses the impact of the phase 3 SORAYA trial in folate receptor alpha–positive ovarian cancer.
October 26, 2022
Article
Rodney Rocconi, MD, discusses the continued exploration of antibody-drug conjugates in patients with ovarian cancer, biomarkers and agents under investigation in the space, and the ongoing research being conducted at the O'Neal Comprehensive Cancer Center.
August 04, 2022
Article
The O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham has been awarded a five-year Cancer Center Core Support Grant of $27,477,570 from the National Cancer Institute.
July 27, 2022
Article
TogetHER for Health is honoring the contributions of the University of Alabama at Birmingham’s Isabel Scarinci, PhD, with the first-ever Trailblazer Award for her tireless dedication to saving women’s lives both in Alabama and across the world.
July 26, 2022
Article
Casey Weaver, MD, the Wyatt and Susan Haskell Endowed Chair for Medical Excellence in the Department of Pathology, was elected to the prestigious and esteemed National Academy of Sciences.
December 20, 2021
Article
The potent, highly selective, next-generation PI3Kδ inhibitor parsaclisib demonstrated activity and an acceptable safety profile in patients with Bruton tyrosine kinase inhibitor-naïve relapsed/refractory mantle cell lymphoma.
July 02, 2021
Article
This coalition of clinical research sites will partner with Genentech to advance the representation of diverse patient populations in the company’s oncology clinical trials.
May 14, 2021
Article
Amitkumar Mehta, MD, the safety profile of liso-cel and how it is advancing the relapsed/refractory large B-cell lymphoma treatment paradigm.
April 14, 2021
Video
Luciano J. Costa, MD, PhD, discusses the evolving treatment paradigm in newly diagnosed multiple myeloma.
November 12, 2020
Video
Monica L. Baskin, PhD, discusses mitigating patient concerns during the coronavirus disease 2019 pandemic in prostate cancer.
October 23, 2020
Video
Monica L. Baskin, PhD, discusses treatment considerations in prostate cancer.
September 22, 2020
Article
Kelly Godby, MD, discusses novel triplet combinations and how they are leading the key developments made in the treatment of patients with relapsed/refractory multiple myeloma in recent years.
September 17, 2020
Article
Susan Bal, MD, discusses key trials in the multiple myeloma space.
September 14, 2020
Video
Luciano J. Costa, MD, PhD, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.
September 09, 2020
Video
Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.
August 24, 2020
Article
Luciano J. Costa, MD, discusses the emerging role of CAR T-cell therapy in relapsed/refractory multiple myeloma, investigational products such as ide-cel, orva-cel, and JNJ-4528, and early intervention strategies to manage the toxicities associated with these products.
August 06, 2020
Video
Luciano J. Costa, MD, PhD, discusses unmet needs in relapsed/refractory multiple myeloma.